Blackstone Participates in $2.5 Billion Financing for Shield's Acquisition of Echodyne
Funds managed by Blackstone are providing a $1 billion structured equity investment to support Shield's $5.3 billion acquisition of Echodyne.
Stocks · News reference
8-K filing — Blackstone Inc. (BX)
Filed: 2026-11-02 AccNo: 0001193125-26-443854 Size: 822 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Blackstone Apartment Income REIT Secures $3.3 Billion CMBS Refinancing
Blackstone Apartment Income REIT is refinancing a portfolio of 29 multifamily properties with a $3.3 billion commercial mortgage-backed securities (CMBS) loan.
Blackstone Raises Approximately $14.62 Billion for European Direct Lending Fund
Blackstone has successfully raised about $14.62 billion (13 billion euros) for its latest European direct lending strategy.
Blackstone President Jon Gray Discusses Market Concentration and AI Infrastructure
Blackstone President and COO Jon Gray addressed concerns regarding market concentration and the potential for an 'AI bubble' at the Global Financial Leaders' Investment Summit.
Blackstone Completes $1.1 Billion Senior Notes Offering
Blackstone Inc. has finalized the offering of $1.1 billion in aggregate principal amount of senior notes, consisting of $600 million due in 2031 and $500 million due in 2033.
Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement
Rhythm Pharmaceuticals amended its global licensing agreement with LG Chem for bivamelagon, reducing royalties from low-to-mid-single digits to 1% on MC4R agonist sales while committing to $350 million in fixed payments over four years. The company also secured a $750 million term-loan facility led by KKR's HealthCare Royalty and Blackstone to support the agreement, commercialization efforts, and pipeline development.